The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

A major new study finds that certain diabetes medications, including GLP-1 and SGLT2 inhibitors, may be linked to a reduced ...

The growing prevalence of diabetes, primarily due to obesity, aging populations, and sedentary lifestyles, is a key factor ...

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.

It’s possible that they may play a role as a preventative measure in the future,” said Dr. Catriona Reddin told The Post.

Research shows diabetes medications may cut Alzheimer's risk by up to 43% in patients with type 2 diabetes, offering ...

GLP-1 receptor agonists and SGLT2 inhibitors are associated with a lower risk of dementia, suggesting these drugs may have a ...

GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this.

Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person’s risk of dementia, a new ...

In addition to GLP-1 medications, a class of medications used in type 2 diabetes called SGLT-2 inhibitors is also being studied for use with type 1 diabetes. GLP-1 drugs can help lower the amount ...